Universitа Cattolica S. Cuore - Ematologia
Welcome,         Profile    Billing    Logout  
 14 Trials 
51 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Hohaus, Stefan
ECHELON-3, NCT04404283 / 2020-002686-33: Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL

Hourglass Jan 2023 - Dec 2023 : From:ECHELON-3 trial in combination with brentuximab vedotin and rituximab for r/r DLBCL
Active, not recruiting
3
241
Europe, Canada, US, RoW
Brentuximab vedotin, Rituximab, Lenalidomide, Placebo
Seagen, a wholly owned subsidiary of Pfizer
Diffuse Large B-cell Lymphoma
11/25
11/25
FIL_PREVID, NCT04442412 / 2019-004474-26: Prephase Treatment With Prednisone +/- Vitamin D Supplementation Followed by Immunochemotherapy

Recruiting
3
430
Europe
Vitamin D3 (Cholecalciferol), RCHOP o R-miniCHOP at standard doses
Fondazione Italiana Linfomi ONLUS, GRADE Onlus
Diffuse Large B-Cell Lymphoma, Elderly Patients
09/25
09/30
SYMPHONY-1, NCT04224493 / 2019-003333-42: A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.

Jan 2023 - Dec 2024: Data from trial for hematological malignancies
Hourglass Jan 2023 - Dec 2023 : First interim futility data from P3 portion of P1b/3 SYMPHONY-1 trial in combination with Rituxan for relapsed/refractory follicular lymphoma
Jan 2023 - Dec 2023: DOR/PFS data from P1b portion of P1b/3 SYMPHONY-1 trial in combination with Revlimid and Rituxan for relapsed/refractory follicular lymphoma
Hourglass Jan 2022 - Dec 2022 : Completion of enrollment of P3 portion of P1b/3 trial for r/r follicular lymphoma
Checkmark Data from SYMPHONY-1 trial in combination with Rituxan and Revlimid for follicular lymphoma
More
Recruiting
3
612
Europe, Canada, US, RoW
Tazemetostat, EPZ-6438, IPN60200, Placebo oral tablet, Lenalidomide, Rituximab
Epizyme, Inc.
Relapsed/Refractory Follicular Lymphoma, Follicular Lymphoma, Refractory Follicular Lymphoma
03/26
03/29
FIL_FOLL19, NCT05058404: Shortened vs Standard Chemotherapy Combined With Immunotherapy for the Initial Treatment of Patients With High Tumor Burden Follicular Lymphoma

Recruiting
3
602
Europe
Immunochemotherapy regimen: Rituximab-bendamustine (Arm A), R-Benda, R-bendamustine, Immunochemotherapy regimen: Rituximab-bendamustine (Arm B), Immunochemotherapy regimen: R-CHOP (Arm A), R-CHOP, Immunochemotherapy regimen: R-CHOP (Arm B), Immunochemotherapy regimen: G-bendamustine (Arm A), G-Benda, Immunochemotherapy regimen: G-bendamustine (Arm B), Immunochemotherapy regimen: G-CHOP (Arm A), G-CHOP, Immunochemotherapy regimen: G-CHOP (Arm B), Immunochemotherapy regimen: G-CVP (Arm A), G-CVP, Immunochemotherapy regimen: G-CVP (Arm B)
Fondazione Italiana Linfomi - ETS
Follicular Lymphoma
07/28
07/30
FIL_GAZEBO, NCT05929222: Comparison Between Local Radiotherapy Alone or Combined With Obinutuzumab in Early Stage Follicular Lymphoma: the GAZEBO Trial From the Fondazione Italiana Linfomi

Recruiting
3
190
Europe
Radiotherapy, Radiotherapy plus Obinutuzumab
Fondazione Italiana Linfomi - ETS, Roche Pharma AG
Follicular Lymphoma
04/31
04/31
NCT04442022 / 2020-000605-84: A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) with or Without Selinexor in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma

Recruiting
2/3
501
Europe, US, RoW
Selinexor (combination therapy), Placebo matching for Selinexor (combination therapy), Rituximab (combination therapy), Gemcitabine (combination therapy), Dexamethasone (combination therapy), Cisplatin (combination therapy), Selinexor (continuous therapy), Placebo matching for Selinexor (continuous therapy)
Karyopharm Therapeutics Inc
Relapsed/refractory Diffuse Large B-cell Lymphoma
12/25
12/25
NCT03731234: Ibrutinib + R-CHOP Followed by Ibrutinib Maintenance

Active, not recruiting
2
75
Europe
Ibrutinib, IMBRUVICA (commercial name)
Fondazione Italiana Linfomi - ETS, Janssen-Cilag S.p.A.
DLBCL
07/24
07/27
SAKK 38/19, NCT04604067: Assessing a ctDNA and PET-oriented Therapy in Patients With DLBCL A Multicenter, Open-label, Phase II Trial.

Active, not recruiting
2
260
Europe
Acalabrutinib
Swiss Group for Clinical Cancer Research
Diffuse Large B-cell Lymphoma
10/25
12/30
KCP-330-009, NCT02227251 / 2014-001977-15: Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Checkmark Approved in Taiwan as monotherapy for R/R DLBCL
Oct 2022 - Oct 2022: Approved in Taiwan as monotherapy for R/R DLBCL
Checkmark Submitted NDA in South Korea for rrDLBCL
Jan 2021 - Jan 2021: Submitted NDA in South Korea for rrDLBCL
Checkmark Subset analysis data from SADAL trial for r/r DLBCL at ASH 2020
More
Recruiting
2
244
Europe, Canada, US, RoW
Selinexor, KPT-330
Karyopharm Therapeutics Inc
Diffuse Large B-cell Lymphoma
04/27
11/27
NCT04600804: The Role of 18F-FDG-PET for Staging and Prognostication

Active, not recruiting
N/A
200
Europe
Fondazione Italiana Linfomi - ETS
Mantle Cell Lymphoma
10/23
01/25
NCT04882475: Biological Insights of First Relapsed-refractory Patients With Mantle Cell Lymphoma: the MANTLE-FIRST BIO Study.

Recruiting
N/A
80
Europe
Fondazione Italiana Linfomi - ETS
Mantle Cell Lymphoma
03/25
03/25
NCT06299553: Study to Evaluate the Effectiveness of Tafasitamab in Combination With Lenalidomide Followed by Tafasitamab Monotherapy in Relapsed or Refractory Diffuse Large B-cell Lymphoma Non-transplant Eligible Patients in Italy (PRO-MIND)

Recruiting
N/A
200
Europe
Incyte Biosciences Italy S.r.l, Advice Pharma Group srl
DLBCL - Diffuse Large B Cell Lymphoma
06/25
06/27
NCT05819528: Primary Cardiac Lymphoma: Italian Multicenter Experience

Recruiting
N/A
43
Europe
Fondazione Italiana Linfomi - ETS
Primary Cardiac Lymphoma
04/26
06/26
NCT06156774: SARcopenia and Simplified Geriatric Assessment in Lymphoma Patients Undergoing CAR-T Cell Therapy: the FIL_SAR-CAR Project

Recruiting
N/A
130
Europe
Chimeric Antigen Receptor T-cells (CAR-T) therapy
Fondazione Italiana Linfomi - ETS, Kite, A Gilead Company
Non-hodgkin Lymphoma,B Cell
07/26
07/26
LA-HLH, NCT06585124: Flow Cytometry for the Study of T-Cell Populations in Hemophagocytic Lymphohistiocytosis Associated With Lymphomas

Recruiting
N/A
150
Europe
Flow Cytometry
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Lymphoma, Hemophagocytic Lymphohistiocytoses
05/25
05/26
FIL_PlaLy, NCT06781359: Study on Plasmablastic Lymphoma Patients

Not yet recruiting
N/A
200
Europe
Fondazione Italiana Linfomi - ETS, AIL Roma - Italia, AIL Cuneo - Italia
Plasmablastic Lymphoma
02/28
02/28
CV_CANCER, NCT06664528: Cardiovascular Health in Adult Patients With Cancer Exposed to Cardiotoxic Therapies

Recruiting
N/A
300
Europe
ECHOCARDIOGRAPHY, ELECTROCARDIOGRAPHY (ECG), LABORATORY TESTS
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Cardiac Toxicity, Cancer
11/28
12/28
MIMOSA, NCT05746858: Predictive Biomarkers Including miRNA-based Tumor Signatures in Diffuse Large B Cell Lymphoma (R/R DLBCL)

Not yet recruiting
N/A
300
Europe
no intervention (observational study)
Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Istituti Fisioterapici Ospitalieri, Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale
Diffuse Large B Cell Lymphoma, Relapsed Non-Hodgkin Lymphoma
03/25
03/27
NCT03552003: Study for Elderly (≥ 65 Years) Patients With Classical Hodgkin Lymphoma Undergoing CGA at Diagnosis

Recruiting
N/A
400
Europe
Treatment for clinical practise
Fondazione Italiana Linfomi ONLUS
Classical Hodgkin Lymphoma
01/26
01/26
Nassi, Luca
FIL_GAZEBO, NCT05929222: Comparison Between Local Radiotherapy Alone or Combined With Obinutuzumab in Early Stage Follicular Lymphoma: the GAZEBO Trial From the Fondazione Italiana Linfomi

Recruiting
3
190
Europe
Radiotherapy, Radiotherapy plus Obinutuzumab
Fondazione Italiana Linfomi - ETS, Roche Pharma AG
Follicular Lymphoma
04/31
04/31
FIORELLA, NCT03495960 / 2016-003116-12: Study on Tailored Treatment in Elderly Patients With Newly Diagnosed Primary Lymphoma of Central Nervous System

Completed
2
72
Europe
Rituximab, Methotrexate, Procarbazine, Lenalidomide, Radiotherapy, Temozolomide
International Extranodal Lymphoma Study Group (IELSG)
Primary Central Nervous System Lymphoma
12/24
12/24
FIL_DALYA, NCT04915248 / 2020-000409-94: Study to Evaluate Combined Treatment of Daratumumab, Bortezomib and Dexamethasone in PBL Patients.

Recruiting
2
28
Europe
Daratumumab, Daratumumab sc, Bortezomib, Bortezomib sc, Dexamethasone, Dexamethasone os
Fondazione Italiana Linfomi - ETS, Janssen-Cilag S.p.A.
Plasmablastic Lymphoma
01/25
01/25
FIL_MOZART, NCT06492837: Study With Mosunetuzumab and Zanubrutinib in R/R Follicular Lymphoma Patients

Not yet recruiting
2
56
Europe
Mosunetuzumab in combination with Zanubrutinib, LUNSUMIO in combination with BRUSINKA
Fondazione Italiana Linfomi - ETS
Follicular Lymphoma
09/28
09/33
FIL_COLUMN, NCT05249959: Consolidation With Loncastuximab Tesirine After a Short Course of Immunochemotherapy in BTKi-treated (or Intolerant) Relapsed/Refractory Mantle Cell Lymphoma Patients.

Recruiting
2
49
Europe
Consolidation with ADCT-402 (loncastuximab tesirine) after salvage immunochemotherapy at standard dose (R-BAC, Rituximab - Bendamustine, Ara-C)), Consolidation with ADCT-402 (loncastuximab tesirine) after salvage immunochemotherapy at reduced dose (R-BAC, Rituximab - Bendamustine, Ara-C)
Fondazione Italiana Linfomi - ETS
Relapsed Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma
04/26
04/29
FIL_RICCO, NCT06835530: A Combination of Rituximab and CC-99282 As Front-line Therapy for Older Frail Patients with Diffuse Large B-cells Non-Hodgkin Lymphoma Evaluated with a Simplified Geriatric Assessment (sGA): a Phase II Study of the Fondazione Italiana Linfomi (FIL)

Not yet recruiting
2
47
Europe
Rituximab + Golcadomide (CC-99282)
Fondazione Italiana Linfomi - ETS
Diffuse Large B Cell Non-Hodgkin Lymphoma
04/30
04/30
KCP-330-009, NCT02227251 / 2014-001977-15: Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Checkmark Approved in Taiwan as monotherapy for R/R DLBCL
Oct 2022 - Oct 2022: Approved in Taiwan as monotherapy for R/R DLBCL
Checkmark Submitted NDA in South Korea for rrDLBCL
Jan 2021 - Jan 2021: Submitted NDA in South Korea for rrDLBCL
Checkmark Subset analysis data from SADAL trial for r/r DLBCL at ASH 2020
More
Recruiting
2
244
Europe, Canada, US, RoW
Selinexor, KPT-330
Karyopharm Therapeutics Inc
Diffuse Large B-cell Lymphoma
04/27
11/27
FIL_POLARDHAP, NCT05966233: R-DHAP vs POLA-R-DHAP Followed by Autologous Transplant as First Salvage Treatment in Patient With Relapsed or Refractory Diffuse Large B Cell Lymphoma

Withdrawn
2
150
Europe
R-DHAP, Pola-R-DHAP
Fondazione Italiana Linfomi - ETS, Roche Pharma AG
Diffuse Large B Cell Lymphoma Refractory, Diffuse Large B-cell Lymphoma Recurrent
01/29
01/29
SilOs, NCT06720870: An Italian Multicenter Retrospective Observational Study to Assess Effectiveness and Safety of Siltuximab for Patients with Castleman's Disease Treated in Italy in a Real-life Context

Recruiting
N/A
65
Europe
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Castleman Disease
01/25
01/25
NCT04882475: Biological Insights of First Relapsed-refractory Patients With Mantle Cell Lymphoma: the MANTLE-FIRST BIO Study.

Recruiting
N/A
80
Europe
Fondazione Italiana Linfomi - ETS
Mantle Cell Lymphoma
03/25
03/25
FIL_PlaLy, NCT06781359: Study on Plasmablastic Lymphoma Patients

Not yet recruiting
N/A
200
Europe
Fondazione Italiana Linfomi - ETS, AIL Roma - Italia, AIL Cuneo - Italia
Plasmablastic Lymphoma
02/28
02/28
FIL_MOGA, NCT06113081: Real World Experience With Mogamulizumab in the Treatment of Cutaneous T-cell Lymphoma

Recruiting
N/A
150
Europe
Fondazione Italiana Linfomi - ETS
Cutaneous T Cell Lymphoma, Cutaneous T-Cell Lymphoma/Mycosis Fungoides, Cutaneous T-Cell Lymphoma/Sezary Syndrome
05/25
07/25
NCT03552003: Study for Elderly (≥ 65 Years) Patients With Classical Hodgkin Lymphoma Undergoing CGA at Diagnosis

Recruiting
N/A
400
Europe
Treatment for clinical practise
Fondazione Italiana Linfomi ONLUS
Classical Hodgkin Lymphoma
01/26
01/26
NCT05934084: Lifestyles Implemented-Survivorship Care Plan in Lymphoma Survivors

Recruiting
N/A
552
Europe
Lifestyles Implemented-Survivorship Care Plan (LS-SCP)
Fondazione Italiana Linfomi - ETS
Classical Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma (DLBCL), Primary Mediastinal Large B-cell Lymphoma (PMBCL)
02/26
02/26
FIL_MAB, NCT06008691: A Prospective, Observational Cohort Study on the Clinical Impact of Novel Monoclonal Antibodies in B-cell Non-Hodgkin Lymphoma in Italian Clinical Practice

Recruiting
N/A
1500
Europe
"novel" MAB (alone or in combination)
Fondazione Italiana Linfomi - ETS, Roche Pharma AG
Non-Hodgkin Lymphoma, B-cell
10/38
10/38
Puccini, Benedetta
RENOIR, NCT02390869 / 2012-003392-18: Rituximab and Lenalidomide vs Rituximab Alone as Maintenance After R-chemoterapy for Relapsed/Refractory FL Patients

Active, not recruiting
3
128
Europe
R2-MANT, Rituximab and Lenalidomide (R2), R-MANT, Rituximab (R)
Fondazione Italiana Linfomi - ETS
Lymphoma, Follicular
01/23
08/27
ECHELON-3, NCT04404283 / 2020-002686-33: Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL

Hourglass Jan 2023 - Dec 2023 : From:ECHELON-3 trial in combination with brentuximab vedotin and rituximab for r/r DLBCL
Active, not recruiting
3
241
Europe, Canada, US, RoW
Brentuximab vedotin, Rituximab, Lenalidomide, Placebo
Seagen, a wholly owned subsidiary of Pfizer
Diffuse Large B-cell Lymphoma
11/25
11/25
LOTIS 5, NCT04384484 / 2020-000241-14: Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Checkmark Safety run-in data from LOTIS-5 trial in combination with rituximab in r/r DLBCL at SOHO 2022
Sep 2022 - Sep 2022: Safety run-in data from LOTIS-5 trial in combination with rituximab in r/r DLBCL at SOHO 2022
Hourglass Sep 2021 - Dec 2021 : Submission for r/r DLBCL
Hourglass Nov 2021 - Dec 2021 : From LOTIS 5 trial in combination with rituximab for DLBCL
Active, not recruiting
3
440
Europe, Canada, Japan, US, RoW
Loncastuximab Tesirine, Zynlonta, ADCT-402, Rituximab, Gemcitabine, Oxaliplatin
ADC Therapeutics S.A., ADC Therapeutics SA
Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
06/25
06/28
FIL_PREVID, NCT04442412 / 2019-004474-26: Prephase Treatment With Prednisone +/- Vitamin D Supplementation Followed by Immunochemotherapy

Recruiting
3
430
Europe
Vitamin D3 (Cholecalciferol), RCHOP o R-miniCHOP at standard doses
Fondazione Italiana Linfomi ONLUS, GRADE Onlus
Diffuse Large B-Cell Lymphoma, Elderly Patients
09/25
09/30
SYMPHONY-1, NCT04224493 / 2019-003333-42: A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.

Jan 2023 - Dec 2024: Data from trial for hematological malignancies
Hourglass Jan 2023 - Dec 2023 : First interim futility data from P3 portion of P1b/3 SYMPHONY-1 trial in combination with Rituxan for relapsed/refractory follicular lymphoma
Jan 2023 - Dec 2023: DOR/PFS data from P1b portion of P1b/3 SYMPHONY-1 trial in combination with Revlimid and Rituxan for relapsed/refractory follicular lymphoma
Hourglass Jan 2022 - Dec 2022 : Completion of enrollment of P3 portion of P1b/3 trial for r/r follicular lymphoma
Checkmark Data from SYMPHONY-1 trial in combination with Rituxan and Revlimid for follicular lymphoma
More
Recruiting
3
612
Europe, Canada, US, RoW
Tazemetostat, EPZ-6438, IPN60200, Placebo oral tablet, Lenalidomide, Rituximab
Epizyme, Inc.
Relapsed/Refractory Follicular Lymphoma, Follicular Lymphoma, Refractory Follicular Lymphoma
03/26
03/29
FIL_FOLL19, NCT05058404: Shortened vs Standard Chemotherapy Combined With Immunotherapy for the Initial Treatment of Patients With High Tumor Burden Follicular Lymphoma

Recruiting
3
602
Europe
Immunochemotherapy regimen: Rituximab-bendamustine (Arm A), R-Benda, R-bendamustine, Immunochemotherapy regimen: Rituximab-bendamustine (Arm B), Immunochemotherapy regimen: R-CHOP (Arm A), R-CHOP, Immunochemotherapy regimen: R-CHOP (Arm B), Immunochemotherapy regimen: G-bendamustine (Arm A), G-Benda, Immunochemotherapy regimen: G-bendamustine (Arm B), Immunochemotherapy regimen: G-CHOP (Arm A), G-CHOP, Immunochemotherapy regimen: G-CHOP (Arm B), Immunochemotherapy regimen: G-CVP (Arm A), G-CVP, Immunochemotherapy regimen: G-CVP (Arm B)
Fondazione Italiana Linfomi - ETS
Follicular Lymphoma
07/28
07/30
FIORELLA, NCT03495960 / 2016-003116-12: Study on Tailored Treatment in Elderly Patients With Newly Diagnosed Primary Lymphoma of Central Nervous System

Completed
2
72
Europe
Rituximab, Methotrexate, Procarbazine, Lenalidomide, Radiotherapy, Temozolomide
International Extranodal Lymphoma Study Group (IELSG)
Primary Central Nervous System Lymphoma
12/24
12/24
NCT04600804: The Role of 18F-FDG-PET for Staging and Prognostication

Active, not recruiting
N/A
200
Europe
Fondazione Italiana Linfomi - ETS
Mantle Cell Lymphoma
10/23
01/25
NCT06156774: SARcopenia and Simplified Geriatric Assessment in Lymphoma Patients Undergoing CAR-T Cell Therapy: the FIL_SAR-CAR Project

Recruiting
N/A
130
Europe
Chimeric Antigen Receptor T-cells (CAR-T) therapy
Fondazione Italiana Linfomi - ETS, Kite, A Gilead Company
Non-hodgkin Lymphoma,B Cell
07/26
07/26
FIL_FOLL-BIO, NCT05816850: Multilayer Biological Characterization of Advanced Follicular Lymphoma: a Translational Study From FIL_FOLL12 Trial

Recruiting
N/A
654
Europe
EZH2 mutations/CNAs by droplet digital PCR (ddPCR), EZH2-derived gene expression signature by RNA-Seq
Fondazione Italiana Linfomi - ETS
Follicular Lymphoma
06/25
06/26
NCT06441214: Retrospective-prospective Study to Evaluate Treatment Management and Outcomes of Patients With Waldenström's Macroglobulinemia (WM) Treated in Italy According to the Zanubrutinib (Brukinsa®) Compassionate Use Program (CUP) and in Common Practice Following Commercial Approval.

Not yet recruiting
N/A
125
Europe
Zanubrutinib
Fondazione Italiana Linfomi - ETS
Waldenström's Macroglobulinemia (WM)
07/26
07/26
NCT05524298: Quality of Life on Elderly Patients with Low Grade Non-Hodgkin Lymphoma

Recruiting
N/A
150
Europe
Fondazione Italiana Linfomi - ETS
Low Grade Non-Hodgkin's Lymphoma, Adult
02/25
02/25
Moia, Riccardo
CLL2323, NCT05694312: Ibrutinib for the Treatment of AIHA in Patients With CLL/SLL or CLL-like MBL

Recruiting
2
45
Europe
Ibrutinib 420 mg
Gruppo Italiano Malattie EMatologiche dell'Adulto
Autoimmune Hemolytic Anemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Monoclonal B-Cell Lymphocytosis CLL-Type
05/25
11/26
NCT06588478: A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Recruiting
2
249
Europe, Canada, US, RoW
Pirtobrutinib
Loxo Oncology, Inc., Eli Lilly and Company
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
06/28
12/28
CLL2423, NCT05803395: Incidence of Severe COVID-19 Infection in Patients With CLL or B-NHL Who Received Pre-exposure Prophylaxis With Tixagevimab and Cilgavimab in Italy.

Recruiting
N/A
954
Europe
Gruppo Italiano Malattie EMatologiche dell'Adulto, Fondazione Italiana Linfomi
Chronic Lymphocytic Leukemia, Indolent B-Cell Non-Hodgkin Lymphoma, COVID-19
09/24
09/24
NCT04882475: Biological Insights of First Relapsed-refractory Patients With Mantle Cell Lymphoma: the MANTLE-FIRST BIO Study.

Recruiting
N/A
80
Europe
Fondazione Italiana Linfomi - ETS
Mantle Cell Lymphoma
03/25
03/25
FIL_FOLL-BIO, NCT05816850: Multilayer Biological Characterization of Advanced Follicular Lymphoma: a Translational Study From FIL_FOLL12 Trial

Recruiting
N/A
654
Europe
EZH2 mutations/CNAs by droplet digital PCR (ddPCR), EZH2-derived gene expression signature by RNA-Seq
Fondazione Italiana Linfomi - ETS
Follicular Lymphoma
06/25
06/26
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Hohaus, Stefan
ECHELON-3, NCT04404283 / 2020-002686-33: Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL

Hourglass Jan 2023 - Dec 2023 : From:ECHELON-3 trial in combination with brentuximab vedotin and rituximab for r/r DLBCL
Active, not recruiting
3
241
Europe, Canada, US, RoW
Brentuximab vedotin, Rituximab, Lenalidomide, Placebo
Seagen, a wholly owned subsidiary of Pfizer
Diffuse Large B-cell Lymphoma
11/25
11/25
FIL_PREVID, NCT04442412 / 2019-004474-26: Prephase Treatment With Prednisone +/- Vitamin D Supplementation Followed by Immunochemotherapy

Recruiting
3
430
Europe
Vitamin D3 (Cholecalciferol), RCHOP o R-miniCHOP at standard doses
Fondazione Italiana Linfomi ONLUS, GRADE Onlus
Diffuse Large B-Cell Lymphoma, Elderly Patients
09/25
09/30
SYMPHONY-1, NCT04224493 / 2019-003333-42: A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.

Jan 2023 - Dec 2024: Data from trial for hematological malignancies
Hourglass Jan 2023 - Dec 2023 : First interim futility data from P3 portion of P1b/3 SYMPHONY-1 trial in combination with Rituxan for relapsed/refractory follicular lymphoma
Jan 2023 - Dec 2023: DOR/PFS data from P1b portion of P1b/3 SYMPHONY-1 trial in combination with Revlimid and Rituxan for relapsed/refractory follicular lymphoma
Hourglass Jan 2022 - Dec 2022 : Completion of enrollment of P3 portion of P1b/3 trial for r/r follicular lymphoma
Checkmark Data from SYMPHONY-1 trial in combination with Rituxan and Revlimid for follicular lymphoma
More
Recruiting
3
612
Europe, Canada, US, RoW
Tazemetostat, EPZ-6438, IPN60200, Placebo oral tablet, Lenalidomide, Rituximab
Epizyme, Inc.
Relapsed/Refractory Follicular Lymphoma, Follicular Lymphoma, Refractory Follicular Lymphoma
03/26
03/29
FIL_FOLL19, NCT05058404: Shortened vs Standard Chemotherapy Combined With Immunotherapy for the Initial Treatment of Patients With High Tumor Burden Follicular Lymphoma

Recruiting
3
602
Europe
Immunochemotherapy regimen: Rituximab-bendamustine (Arm A), R-Benda, R-bendamustine, Immunochemotherapy regimen: Rituximab-bendamustine (Arm B), Immunochemotherapy regimen: R-CHOP (Arm A), R-CHOP, Immunochemotherapy regimen: R-CHOP (Arm B), Immunochemotherapy regimen: G-bendamustine (Arm A), G-Benda, Immunochemotherapy regimen: G-bendamustine (Arm B), Immunochemotherapy regimen: G-CHOP (Arm A), G-CHOP, Immunochemotherapy regimen: G-CHOP (Arm B), Immunochemotherapy regimen: G-CVP (Arm A), G-CVP, Immunochemotherapy regimen: G-CVP (Arm B)
Fondazione Italiana Linfomi - ETS
Follicular Lymphoma
07/28
07/30
FIL_GAZEBO, NCT05929222: Comparison Between Local Radiotherapy Alone or Combined With Obinutuzumab in Early Stage Follicular Lymphoma: the GAZEBO Trial From the Fondazione Italiana Linfomi

Recruiting
3
190
Europe
Radiotherapy, Radiotherapy plus Obinutuzumab
Fondazione Italiana Linfomi - ETS, Roche Pharma AG
Follicular Lymphoma
04/31
04/31
NCT04442022 / 2020-000605-84: A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) with or Without Selinexor in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma

Recruiting
2/3
501
Europe, US, RoW
Selinexor (combination therapy), Placebo matching for Selinexor (combination therapy), Rituximab (combination therapy), Gemcitabine (combination therapy), Dexamethasone (combination therapy), Cisplatin (combination therapy), Selinexor (continuous therapy), Placebo matching for Selinexor (continuous therapy)
Karyopharm Therapeutics Inc
Relapsed/refractory Diffuse Large B-cell Lymphoma
12/25
12/25
NCT03731234: Ibrutinib + R-CHOP Followed by Ibrutinib Maintenance

Active, not recruiting
2
75
Europe
Ibrutinib, IMBRUVICA (commercial name)
Fondazione Italiana Linfomi - ETS, Janssen-Cilag S.p.A.
DLBCL
07/24
07/27
SAKK 38/19, NCT04604067: Assessing a ctDNA and PET-oriented Therapy in Patients With DLBCL A Multicenter, Open-label, Phase II Trial.

Active, not recruiting
2
260
Europe
Acalabrutinib
Swiss Group for Clinical Cancer Research
Diffuse Large B-cell Lymphoma
10/25
12/30
KCP-330-009, NCT02227251 / 2014-001977-15: Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Checkmark Approved in Taiwan as monotherapy for R/R DLBCL
Oct 2022 - Oct 2022: Approved in Taiwan as monotherapy for R/R DLBCL
Checkmark Submitted NDA in South Korea for rrDLBCL
Jan 2021 - Jan 2021: Submitted NDA in South Korea for rrDLBCL
Checkmark Subset analysis data from SADAL trial for r/r DLBCL at ASH 2020
More
Recruiting
2
244
Europe, Canada, US, RoW
Selinexor, KPT-330
Karyopharm Therapeutics Inc
Diffuse Large B-cell Lymphoma
04/27
11/27
NCT04600804: The Role of 18F-FDG-PET for Staging and Prognostication

Active, not recruiting
N/A
200
Europe
Fondazione Italiana Linfomi - ETS
Mantle Cell Lymphoma
10/23
01/25
NCT04882475: Biological Insights of First Relapsed-refractory Patients With Mantle Cell Lymphoma: the MANTLE-FIRST BIO Study.

Recruiting
N/A
80
Europe
Fondazione Italiana Linfomi - ETS
Mantle Cell Lymphoma
03/25
03/25
NCT06299553: Study to Evaluate the Effectiveness of Tafasitamab in Combination With Lenalidomide Followed by Tafasitamab Monotherapy in Relapsed or Refractory Diffuse Large B-cell Lymphoma Non-transplant Eligible Patients in Italy (PRO-MIND)

Recruiting
N/A
200
Europe
Incyte Biosciences Italy S.r.l, Advice Pharma Group srl
DLBCL - Diffuse Large B Cell Lymphoma
06/25
06/27
NCT05819528: Primary Cardiac Lymphoma: Italian Multicenter Experience

Recruiting
N/A
43
Europe
Fondazione Italiana Linfomi - ETS
Primary Cardiac Lymphoma
04/26
06/26
NCT06156774: SARcopenia and Simplified Geriatric Assessment in Lymphoma Patients Undergoing CAR-T Cell Therapy: the FIL_SAR-CAR Project

Recruiting
N/A
130
Europe
Chimeric Antigen Receptor T-cells (CAR-T) therapy
Fondazione Italiana Linfomi - ETS, Kite, A Gilead Company
Non-hodgkin Lymphoma,B Cell
07/26
07/26
LA-HLH, NCT06585124: Flow Cytometry for the Study of T-Cell Populations in Hemophagocytic Lymphohistiocytosis Associated With Lymphomas

Recruiting
N/A
150
Europe
Flow Cytometry
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Lymphoma, Hemophagocytic Lymphohistiocytoses
05/25
05/26
FIL_PlaLy, NCT06781359: Study on Plasmablastic Lymphoma Patients

Not yet recruiting
N/A
200
Europe
Fondazione Italiana Linfomi - ETS, AIL Roma - Italia, AIL Cuneo - Italia
Plasmablastic Lymphoma
02/28
02/28
CV_CANCER, NCT06664528: Cardiovascular Health in Adult Patients With Cancer Exposed to Cardiotoxic Therapies

Recruiting
N/A
300
Europe
ECHOCARDIOGRAPHY, ELECTROCARDIOGRAPHY (ECG), LABORATORY TESTS
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Cardiac Toxicity, Cancer
11/28
12/28
MIMOSA, NCT05746858: Predictive Biomarkers Including miRNA-based Tumor Signatures in Diffuse Large B Cell Lymphoma (R/R DLBCL)

Not yet recruiting
N/A
300
Europe
no intervention (observational study)
Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Istituti Fisioterapici Ospitalieri, Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale
Diffuse Large B Cell Lymphoma, Relapsed Non-Hodgkin Lymphoma
03/25
03/27
NCT03552003: Study for Elderly (≥ 65 Years) Patients With Classical Hodgkin Lymphoma Undergoing CGA at Diagnosis

Recruiting
N/A
400
Europe
Treatment for clinical practise
Fondazione Italiana Linfomi ONLUS
Classical Hodgkin Lymphoma
01/26
01/26
Nassi, Luca
FIL_GAZEBO, NCT05929222: Comparison Between Local Radiotherapy Alone or Combined With Obinutuzumab in Early Stage Follicular Lymphoma: the GAZEBO Trial From the Fondazione Italiana Linfomi

Recruiting
3
190
Europe
Radiotherapy, Radiotherapy plus Obinutuzumab
Fondazione Italiana Linfomi - ETS, Roche Pharma AG
Follicular Lymphoma
04/31
04/31
FIORELLA, NCT03495960 / 2016-003116-12: Study on Tailored Treatment in Elderly Patients With Newly Diagnosed Primary Lymphoma of Central Nervous System

Completed
2
72
Europe
Rituximab, Methotrexate, Procarbazine, Lenalidomide, Radiotherapy, Temozolomide
International Extranodal Lymphoma Study Group (IELSG)
Primary Central Nervous System Lymphoma
12/24
12/24
FIL_DALYA, NCT04915248 / 2020-000409-94: Study to Evaluate Combined Treatment of Daratumumab, Bortezomib and Dexamethasone in PBL Patients.

Recruiting
2
28
Europe
Daratumumab, Daratumumab sc, Bortezomib, Bortezomib sc, Dexamethasone, Dexamethasone os
Fondazione Italiana Linfomi - ETS, Janssen-Cilag S.p.A.
Plasmablastic Lymphoma
01/25
01/25
FIL_MOZART, NCT06492837: Study With Mosunetuzumab and Zanubrutinib in R/R Follicular Lymphoma Patients

Not yet recruiting
2
56
Europe
Mosunetuzumab in combination with Zanubrutinib, LUNSUMIO in combination with BRUSINKA
Fondazione Italiana Linfomi - ETS
Follicular Lymphoma
09/28
09/33
FIL_COLUMN, NCT05249959: Consolidation With Loncastuximab Tesirine After a Short Course of Immunochemotherapy in BTKi-treated (or Intolerant) Relapsed/Refractory Mantle Cell Lymphoma Patients.

Recruiting
2
49
Europe
Consolidation with ADCT-402 (loncastuximab tesirine) after salvage immunochemotherapy at standard dose (R-BAC, Rituximab - Bendamustine, Ara-C)), Consolidation with ADCT-402 (loncastuximab tesirine) after salvage immunochemotherapy at reduced dose (R-BAC, Rituximab - Bendamustine, Ara-C)
Fondazione Italiana Linfomi - ETS
Relapsed Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma
04/26
04/29
FIL_RICCO, NCT06835530: A Combination of Rituximab and CC-99282 As Front-line Therapy for Older Frail Patients with Diffuse Large B-cells Non-Hodgkin Lymphoma Evaluated with a Simplified Geriatric Assessment (sGA): a Phase II Study of the Fondazione Italiana Linfomi (FIL)

Not yet recruiting
2
47
Europe
Rituximab + Golcadomide (CC-99282)
Fondazione Italiana Linfomi - ETS
Diffuse Large B Cell Non-Hodgkin Lymphoma
04/30
04/30
KCP-330-009, NCT02227251 / 2014-001977-15: Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Checkmark Approved in Taiwan as monotherapy for R/R DLBCL
Oct 2022 - Oct 2022: Approved in Taiwan as monotherapy for R/R DLBCL
Checkmark Submitted NDA in South Korea for rrDLBCL
Jan 2021 - Jan 2021: Submitted NDA in South Korea for rrDLBCL
Checkmark Subset analysis data from SADAL trial for r/r DLBCL at ASH 2020
More
Recruiting
2
244
Europe, Canada, US, RoW
Selinexor, KPT-330
Karyopharm Therapeutics Inc
Diffuse Large B-cell Lymphoma
04/27
11/27
FIL_POLARDHAP, NCT05966233: R-DHAP vs POLA-R-DHAP Followed by Autologous Transplant as First Salvage Treatment in Patient With Relapsed or Refractory Diffuse Large B Cell Lymphoma

Withdrawn
2
150
Europe
R-DHAP, Pola-R-DHAP
Fondazione Italiana Linfomi - ETS, Roche Pharma AG
Diffuse Large B Cell Lymphoma Refractory, Diffuse Large B-cell Lymphoma Recurrent
01/29
01/29
SilOs, NCT06720870: An Italian Multicenter Retrospective Observational Study to Assess Effectiveness and Safety of Siltuximab for Patients with Castleman's Disease Treated in Italy in a Real-life Context

Recruiting
N/A
65
Europe
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Castleman Disease
01/25
01/25
NCT04882475: Biological Insights of First Relapsed-refractory Patients With Mantle Cell Lymphoma: the MANTLE-FIRST BIO Study.

Recruiting
N/A
80
Europe
Fondazione Italiana Linfomi - ETS
Mantle Cell Lymphoma
03/25
03/25
FIL_PlaLy, NCT06781359: Study on Plasmablastic Lymphoma Patients

Not yet recruiting
N/A
200
Europe
Fondazione Italiana Linfomi - ETS, AIL Roma - Italia, AIL Cuneo - Italia
Plasmablastic Lymphoma
02/28
02/28
FIL_MOGA, NCT06113081: Real World Experience With Mogamulizumab in the Treatment of Cutaneous T-cell Lymphoma

Recruiting
N/A
150
Europe
Fondazione Italiana Linfomi - ETS
Cutaneous T Cell Lymphoma, Cutaneous T-Cell Lymphoma/Mycosis Fungoides, Cutaneous T-Cell Lymphoma/Sezary Syndrome
05/25
07/25
NCT03552003: Study for Elderly (≥ 65 Years) Patients With Classical Hodgkin Lymphoma Undergoing CGA at Diagnosis

Recruiting
N/A
400
Europe
Treatment for clinical practise
Fondazione Italiana Linfomi ONLUS
Classical Hodgkin Lymphoma
01/26
01/26
NCT05934084: Lifestyles Implemented-Survivorship Care Plan in Lymphoma Survivors

Recruiting
N/A
552
Europe
Lifestyles Implemented-Survivorship Care Plan (LS-SCP)
Fondazione Italiana Linfomi - ETS
Classical Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma (DLBCL), Primary Mediastinal Large B-cell Lymphoma (PMBCL)
02/26
02/26
FIL_MAB, NCT06008691: A Prospective, Observational Cohort Study on the Clinical Impact of Novel Monoclonal Antibodies in B-cell Non-Hodgkin Lymphoma in Italian Clinical Practice

Recruiting
N/A
1500
Europe
"novel" MAB (alone or in combination)
Fondazione Italiana Linfomi - ETS, Roche Pharma AG
Non-Hodgkin Lymphoma, B-cell
10/38
10/38
Puccini, Benedetta
RENOIR, NCT02390869 / 2012-003392-18: Rituximab and Lenalidomide vs Rituximab Alone as Maintenance After R-chemoterapy for Relapsed/Refractory FL Patients

Active, not recruiting
3
128
Europe
R2-MANT, Rituximab and Lenalidomide (R2), R-MANT, Rituximab (R)
Fondazione Italiana Linfomi - ETS
Lymphoma, Follicular
01/23
08/27
ECHELON-3, NCT04404283 / 2020-002686-33: Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL

Hourglass Jan 2023 - Dec 2023 : From:ECHELON-3 trial in combination with brentuximab vedotin and rituximab for r/r DLBCL
Active, not recruiting
3
241
Europe, Canada, US, RoW
Brentuximab vedotin, Rituximab, Lenalidomide, Placebo
Seagen, a wholly owned subsidiary of Pfizer
Diffuse Large B-cell Lymphoma
11/25
11/25
LOTIS 5, NCT04384484 / 2020-000241-14: Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Checkmark Safety run-in data from LOTIS-5 trial in combination with rituximab in r/r DLBCL at SOHO 2022
Sep 2022 - Sep 2022: Safety run-in data from LOTIS-5 trial in combination with rituximab in r/r DLBCL at SOHO 2022
Hourglass Sep 2021 - Dec 2021 : Submission for r/r DLBCL
Hourglass Nov 2021 - Dec 2021 : From LOTIS 5 trial in combination with rituximab for DLBCL
Active, not recruiting
3
440
Europe, Canada, Japan, US, RoW
Loncastuximab Tesirine, Zynlonta, ADCT-402, Rituximab, Gemcitabine, Oxaliplatin
ADC Therapeutics S.A., ADC Therapeutics SA
Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
06/25
06/28
FIL_PREVID, NCT04442412 / 2019-004474-26: Prephase Treatment With Prednisone +/- Vitamin D Supplementation Followed by Immunochemotherapy

Recruiting
3
430
Europe
Vitamin D3 (Cholecalciferol), RCHOP o R-miniCHOP at standard doses
Fondazione Italiana Linfomi ONLUS, GRADE Onlus
Diffuse Large B-Cell Lymphoma, Elderly Patients
09/25
09/30
SYMPHONY-1, NCT04224493 / 2019-003333-42: A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.

Jan 2023 - Dec 2024: Data from trial for hematological malignancies
Hourglass Jan 2023 - Dec 2023 : First interim futility data from P3 portion of P1b/3 SYMPHONY-1 trial in combination with Rituxan for relapsed/refractory follicular lymphoma
Jan 2023 - Dec 2023: DOR/PFS data from P1b portion of P1b/3 SYMPHONY-1 trial in combination with Revlimid and Rituxan for relapsed/refractory follicular lymphoma
Hourglass Jan 2022 - Dec 2022 : Completion of enrollment of P3 portion of P1b/3 trial for r/r follicular lymphoma
Checkmark Data from SYMPHONY-1 trial in combination with Rituxan and Revlimid for follicular lymphoma
More
Recruiting
3
612
Europe, Canada, US, RoW
Tazemetostat, EPZ-6438, IPN60200, Placebo oral tablet, Lenalidomide, Rituximab
Epizyme, Inc.
Relapsed/Refractory Follicular Lymphoma, Follicular Lymphoma, Refractory Follicular Lymphoma
03/26
03/29
FIL_FOLL19, NCT05058404: Shortened vs Standard Chemotherapy Combined With Immunotherapy for the Initial Treatment of Patients With High Tumor Burden Follicular Lymphoma

Recruiting
3
602
Europe
Immunochemotherapy regimen: Rituximab-bendamustine (Arm A), R-Benda, R-bendamustine, Immunochemotherapy regimen: Rituximab-bendamustine (Arm B), Immunochemotherapy regimen: R-CHOP (Arm A), R-CHOP, Immunochemotherapy regimen: R-CHOP (Arm B), Immunochemotherapy regimen: G-bendamustine (Arm A), G-Benda, Immunochemotherapy regimen: G-bendamustine (Arm B), Immunochemotherapy regimen: G-CHOP (Arm A), G-CHOP, Immunochemotherapy regimen: G-CHOP (Arm B), Immunochemotherapy regimen: G-CVP (Arm A), G-CVP, Immunochemotherapy regimen: G-CVP (Arm B)
Fondazione Italiana Linfomi - ETS
Follicular Lymphoma
07/28
07/30
FIORELLA, NCT03495960 / 2016-003116-12: Study on Tailored Treatment in Elderly Patients With Newly Diagnosed Primary Lymphoma of Central Nervous System

Completed
2
72
Europe
Rituximab, Methotrexate, Procarbazine, Lenalidomide, Radiotherapy, Temozolomide
International Extranodal Lymphoma Study Group (IELSG)
Primary Central Nervous System Lymphoma
12/24
12/24
NCT04600804: The Role of 18F-FDG-PET for Staging and Prognostication

Active, not recruiting
N/A
200
Europe
Fondazione Italiana Linfomi - ETS
Mantle Cell Lymphoma
10/23
01/25
NCT06156774: SARcopenia and Simplified Geriatric Assessment in Lymphoma Patients Undergoing CAR-T Cell Therapy: the FIL_SAR-CAR Project

Recruiting
N/A
130
Europe
Chimeric Antigen Receptor T-cells (CAR-T) therapy
Fondazione Italiana Linfomi - ETS, Kite, A Gilead Company
Non-hodgkin Lymphoma,B Cell
07/26
07/26
FIL_FOLL-BIO, NCT05816850: Multilayer Biological Characterization of Advanced Follicular Lymphoma: a Translational Study From FIL_FOLL12 Trial

Recruiting
N/A
654
Europe
EZH2 mutations/CNAs by droplet digital PCR (ddPCR), EZH2-derived gene expression signature by RNA-Seq
Fondazione Italiana Linfomi - ETS
Follicular Lymphoma
06/25
06/26
NCT06441214: Retrospective-prospective Study to Evaluate Treatment Management and Outcomes of Patients With Waldenström's Macroglobulinemia (WM) Treated in Italy According to the Zanubrutinib (Brukinsa®) Compassionate Use Program (CUP) and in Common Practice Following Commercial Approval.

Not yet recruiting
N/A
125
Europe
Zanubrutinib
Fondazione Italiana Linfomi - ETS
Waldenström's Macroglobulinemia (WM)
07/26
07/26
NCT05524298: Quality of Life on Elderly Patients with Low Grade Non-Hodgkin Lymphoma

Recruiting
N/A
150
Europe
Fondazione Italiana Linfomi - ETS
Low Grade Non-Hodgkin's Lymphoma, Adult
02/25
02/25
Moia, Riccardo
CLL2323, NCT05694312: Ibrutinib for the Treatment of AIHA in Patients With CLL/SLL or CLL-like MBL

Recruiting
2
45
Europe
Ibrutinib 420 mg
Gruppo Italiano Malattie EMatologiche dell'Adulto
Autoimmune Hemolytic Anemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Monoclonal B-Cell Lymphocytosis CLL-Type
05/25
11/26
NCT06588478: A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Recruiting
2
249
Europe, Canada, US, RoW
Pirtobrutinib
Loxo Oncology, Inc., Eli Lilly and Company
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
06/28
12/28
CLL2423, NCT05803395: Incidence of Severe COVID-19 Infection in Patients With CLL or B-NHL Who Received Pre-exposure Prophylaxis With Tixagevimab and Cilgavimab in Italy.

Recruiting
N/A
954
Europe
Gruppo Italiano Malattie EMatologiche dell'Adulto, Fondazione Italiana Linfomi
Chronic Lymphocytic Leukemia, Indolent B-Cell Non-Hodgkin Lymphoma, COVID-19
09/24
09/24
NCT04882475: Biological Insights of First Relapsed-refractory Patients With Mantle Cell Lymphoma: the MANTLE-FIRST BIO Study.

Recruiting
N/A
80
Europe
Fondazione Italiana Linfomi - ETS
Mantle Cell Lymphoma
03/25
03/25
FIL_FOLL-BIO, NCT05816850: Multilayer Biological Characterization of Advanced Follicular Lymphoma: a Translational Study From FIL_FOLL12 Trial

Recruiting
N/A
654
Europe
EZH2 mutations/CNAs by droplet digital PCR (ddPCR), EZH2-derived gene expression signature by RNA-Seq
Fondazione Italiana Linfomi - ETS
Follicular Lymphoma
06/25
06/26

Download Options